Ultime notizie per Kane Biotech (OTC:KNBIF) Azioni

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.

KANE BIOTECH INC ORD by Kane Biotech Inc.

Kane Biotech Inc

Kane Biotech enters into agreement to amend its credit facility

Kane Biotech GAAP EPS of -$0.01

Kane Biotech GAAP EPS of -$0.01, revenue of $0.94M

Kane Biotech signs license deal with Omni Bioceutical for its scalp care products

Kane Biotech GAAP EPS of $0.07, revenue of $810.3M

KNBIF

Press Releases

Kane Biotech to Participate in a Multinational Corporate Collaboration Project

Kane Biotech Announces Exclusive Distribution Agreement With XSONX

Health Care

Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine

News

Kane Biotech Announces Agreement to Acquire FB Dermatology

Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement

General

Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

TSXV:KNE

Kane Biotech

Comments

Kane Biotech

Notizie

Ultime notizie per Kane Biotech (OTC:KNBIF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO